
VTYX
Ventyx Biosciences Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.210
Open
3.170
VWAP
3.17
Vol
470.18K
Mkt Cap
226.29M
Low
3.130
Amount
1.49M
EV/EBITDA(TTM)
--
Total Shares
70.50M
EV
-2.51M
EV/OCF(TTM)
--
P/S(TTM)
--
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Show More
8 Analyst Rating

258.49% Upside
Wall Street analysts forecast VTYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTYX is 11.40 USD with a low forecast of 2.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
3 Hold
0 Sell
Moderate Buy

258.49% Upside
Current: 3.180

Low
2.00
Averages
11.40
High
21.00

258.49% Upside
Current: 3.180

Low
2.00
Averages
11.40
High
21.00
HC Wainwright & Co.
Emily Bodnar
Hold
Reiterates
n/a
2025-01-14
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
n/a
2025-01-14
Reiterates
Hold
Reason
HC Wainwright & Co.
Emily Bodnar
Hold
Reiterates
$6
2024-11-11
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$6
2024-11-11
Reiterates
Hold
Reason
Oppenheimer
Jeff Jones
Buy
Reiterates
$10 → $9
2024-11-08
Reason
Oppenheimer
Jeff Jones
Price Target
$10 → $9
2024-11-08
Reiterates
Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Hold
Reiterates
$6
2024-10-15
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$6
2024-10-15
Reiterates
Hold
Reason
HC Wainwright & Co.
Emily Bodnar
Hold
Reiterates
$6
2024-09-23
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$6
2024-09-23
Reiterates
Hold
Reason
Canaccord Genuity
Edward Nash
Strong Buy
Maintains
$15 → $14
2024-08-12
Reason
Canaccord Genuity
Edward Nash
Price Target
$15 → $14
2024-08-12
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Ventyx Biosciences Inc (VTYX.O) is -1.58, compared to its 5-year average forward P/E of -5.80. For a more detailed relative valuation and DCF analysis to assess Ventyx Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-5.80
Current PE
-1.58
Overvalued PE
-1.17
Undervalued PE
-10.43
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-3.82
Current EV/EBITDA
-0.08
Overvalued EV/EBITDA
0.96
Undervalued EV/EBITDA
-8.60
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
-27.94%
-30.10M
Operating Profit
FY2025Q1
YoY :
-28.86%
-27.44M
Net Income after Tax
FY2025Q1
YoY :
-37.10%
-0.39
EPS - Diluted
FY2025Q1
YoY :
-46.16%
-25.73M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
2.0K
USD
1
6-9
Months
79.5K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
3
1.3M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 427.27% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
8.2M
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
1.4M
Volume
Months
6-9
1
275.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
2.0K
USD
1
6-9
Months
79.5K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
3
1.3M
USD
Months
0-12
0
0.0
USD
Months
VTYX News & Events
Events Timeline
2025-06-17 (ET)
2025-06-17
07:05:07
Ventyx announces Phase 2a study of VTX3232 accomplished primary objective

2025-05-08 (ET)
2025-05-08
16:16:06
Ventyx Biosciences reports Q1 EPS (39c), consensus (48c)

2025-04-01 (ET)
2025-04-01
07:24:10
Ventyx Biosciences announces seven additional appointments to SAB

Sign Up For More Events
Sign Up For More Events
News
9.0
06-17SeekingAlphaVentyx says Parkinson’s disease drug hit main goal in small mid-stage trial
5.0
04-01NewsfilterVentyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists
9.0
03-08SeekingAlphaWeight-loss drug battle: Who are the latest players involved
Sign Up For More News
People Also Watch

SGMT
Sagimet Biosciences Inc
10.240
USD
+0.39%

VERU
Veru Inc
0.561
USD
-6.50%

CTGO
Contango ORE Inc
19.910
USD
-2.21%

TSQ
Townsquare Media Inc
7.320
USD
+0.97%

ALTO
Alto Ingredients Inc
1.180
USD
0.00%

OPRT
Oportun Financial Corp
6.360
USD
+0.95%

WHG
Westwood Holdings Group Inc
18.030
USD
+0.22%

TDTH
Trident Digital Tech Holdings Ltd
1.340
USD
-0.74%

AMTX
Aemetis Inc
3.190
USD
-2.45%

HOFT
Hooker Furnishings Corp
11.470
USD
+2.23%
FAQ

What is Ventyx Biosciences Inc (VTYX) stock price today?
The current price of VTYX is 3.18 USD — it has decreased -0.63 % in the last trading day.

What is Ventyx Biosciences Inc (VTYX)'s business?

What is the price predicton of VTYX Stock?

What is Ventyx Biosciences Inc (VTYX)'s revenue for the last quarter?

What is Ventyx Biosciences Inc (VTYX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Ventyx Biosciences Inc (VTYX)'s fundamentals?

How many employees does Ventyx Biosciences Inc (VTYX). have?
